Abstract

In recent years, an emerging body of evidence has forged links between Parkinson’s disease (PD) and type 2 diabetes mellitus (T2DM). In observational studies, those with T2DM appear to be at increased risk of developing PD, as well as experiencing faster progression and a more severe phenotype of PD, with the effects being potentially mediated by several common cellular pathways. The insulin signalling pathway, for example, may be responsible for neurodegeneration via insulin dysregulation, aggregation of amyloids, neuroinflammation, mitochondrial dysfunction and altered synaptic plasticity. In light of these potential shared disease mechanisms, clinical trials are now investigating the use of established diabetes drugs targeting insulin resistance in the management of PD. This review will discuss the epidemiological links between T2DM and PD, the potential shared cellular mechanisms, and assess the relevant treatment options for disease modification of PD.

中文翻译：

---

2 型糖尿病与帕金森病之间的关联。

摘要

近年来，越来越多的证据证实帕金森病 (PD) 和 2 型糖尿病 (T2DM) 之间存在联系。在观察性研究中，T2DM 患者患帕金森病的风险似乎更高，并且帕金森病的进展更快，表型更严重，其影响可能是由几种常见的细胞途径介导的。例如，胰岛素信号传导途径可能通过胰岛素失调、淀粉样蛋白聚集、神经炎症、线粒体功能障碍和突触可塑性改变而导致神经变性。鉴于这些潜在的共同疾病机制，临床试验目前正在研究使用现有的针对胰岛素抵抗的糖尿病药物来治疗帕金森病。本综述将讨论 T2DM 和 PD 之间的流行病学联系、潜在的共同细胞机制，并评估 PD 疾病缓解的相关治疗方案。